Cancer Treatment with Cytokines: Concepts and First Clinical Experience

  • A. Lindemann
  • F. Herrmann
  • H. Gamm
  • W. Oster
  • R. Mertelsmann


At present, the treatment of neoplastic disorders is based mainly on local surgical and radiotherapeutic means and the systemic use of cytotoxic drugs. The molecular basis of the differential sensitivity of cancer tissues for these drugs as compared with normal tissues remains, however, largely undefined. It has been postulated that differences in the kinetics of cell proliferation are the basis of this differential sensitivity. This has been demonstrated convincingly, however, for very few neoplastic diseases. Alternative explanations of chemotherapeutic efficacy include a relative decrease in efficient repair mechanisms in cancer cells, as well as chemotherapy-induced reduction of growth factor release, which is required for the proliferation of tumor cells. So far, chemotherapy remains the mainstay for the treatment of disseminated cancer. However, results of chemotherapy have remained largely disappointing, and cure rates been stagnating, especially for the more frequent cancers, such as lung, breast, and colon cancer [1]. Therefore, current researchers are looking for new concepts of cancer treatment based on a more profound understanding of tumor biology.


Renal Cell Cancer Hairy Cell Leukemia Bone Marrow Toxicity Capillary Leakage Syndrome Recombinant Human Tumor Necrosis Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bailar JC, Smith EM (1986) Progress against cancer? N Engl Med J 314: 1226CrossRefGoogle Scholar
  2. 2.
    Vogt PK (1987) Oncogenes and signals of cell growth. Drug Res 37: 243Google Scholar
  3. 3.
    Goyette M, Petrapoulos CJ, Shank PR, Fausto N (1983) Expression of a cellular oncogene during liver regeneration Science 219: 510Google Scholar
  4. 4.
    Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1651Google Scholar
  5. 5.
    Goulomb H, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman J, Burke JS, Brady J, Bonnem E, Spiegel R (1986) Alpha-2 interferon therapy of hairy cell leukemia: a multicenter study of 64 patients. J Clin Oncol 4: 900Google Scholar
  6. 6.
    Talpaz M, Kantarjian HM, Mc Credie K, Trujillo JM, Keating MJ, Gutterman JU (1986) He-matologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314: 1065PubMedCrossRefGoogle Scholar
  7. 7.
    Ozer H, Anderson JR, Peterson BA, Budman DR, Henderson ES, Bloomfield CD, Gottlieb A (1987) Combination trial of subcutaneous interferon alpha-2b and oral cyclophosphamide in favorable histology, non-Hodgkin’s lymphoma. Invest New Drugs 5: 27CrossRefGoogle Scholar
  8. 8.
    Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ (1986) Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiol 172: 275CrossRefGoogle Scholar
  9. 9.
    Muss HB, Constanzi JJ, Leavitt R, Williams RD, Kempf RA, Pollard R, Ozer H, Zekan PJ, Grimberg SU, Metchell US, Caponera M, Gavigan M, Ernest ML, Venturi C, Greiner J, Spiegel RJ (1987) Recombinant alpha interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 5: 286PubMedGoogle Scholar
  10. 10.
    Torti FM, Lum BL, Aston D, MacKenzie N, Faysel M, Shortliffe LD, Freiha F (1986) Superficial bladder cancer: the primacy of grade in the development of invasive disease. Sem Oncol 8 [Suppl 2]: 57Google Scholar
  11. 11.
    Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnern EM, Spiegel RJ, Zighelboim J (1985) Intraperitoneal recombinant alpha-interon for “salvage” immunotherapy in stage III epithelial overarm cancer: a gynecologic oncology group study. Cancer Res 45: 4447PubMedGoogle Scholar
  12. 12.
    Lindemann A, Oster W, Schmidt RE, Höffken K, Herrmann F, Mertelsmann R (1988) Phase- Il-Studie mit rekombinantem humanen Interleukin 2 bei Patienten mit malignem Melanom und Hypernephrom. Klin Wochenschr [Suppl] 66: 252 (abstract 551)Google Scholar
  13. 13.
    Waldmann TA (1986) The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232: 727PubMedCrossRefGoogle Scholar
  14. 14.
    Wang HM, Smith (1987) The interleukin-2 receptor. J Exp Med 166: 1055Google Scholar
  15. 15.
    Siegel JP, Sharon M, Smith KL, Leonard WJ (1987) The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK and proliferative activities. Sciene 238: 75Google Scholar
  16. 16.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg S (1981) Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823CrossRefGoogle Scholar
  17. 17.
    Mule JJ, Shu S, Schwarz L, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 255: 1487CrossRefGoogle Scholar
  18. 18.
    Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169PubMedCrossRefGoogle Scholar
  19. 19.
    Lotze UT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin-2. I. Half life and immunologic effects of the Jurkat cell line- derived interleukin-2. J Immunol 134: 157PubMedGoogle Scholar
  20. 20.
    Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Enger A, Bradley EC, Konrad M, Polivka A, Gabrilove JL, Sykora FW, Miller GA, Fiedler W, Krown S, Oettgen HF, Mertelsmann R (1987) Polyclonal expansion of activated T-lymphocytes in patients treated with recombinant interleukin-2. J Biol Response Mod 6: 412PubMedGoogle Scholar
  21. 21.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Lineken WM, Robertson GN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 55: 1063Google Scholar
  22. 22.
    North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 55: 1063CrossRefGoogle Scholar
  23. 23.
    Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, Oettgen HF, Mertelsmann R (1988) Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. J Biol Response Mod (to be published)Google Scholar
  24. 24.
    West WW, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898PubMedCrossRefGoogle Scholar
  25. 25.
    Herrmann F, Cannistra SA, Lindemann A, Mertelsmann RH, Rambaldi A, Griffin JD (1988) Functional consequences of monocyte interleukin-2 receptor expression: induction of monokines by interferon-gamma and interleukin-2. J Immunol in pressGoogle Scholar
  26. 26.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer MC, Rosenberg SA (1985) In vivo administration of human interleukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135: 2865PubMedGoogle Scholar
  27. 27.
    Thompson JA, Lee DJ, Welby-Cox W, Lindgren CG, Collins C, Neraas KA, Dennin RA, Fefer A (1987) Recombinant interleukin-2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 47: 4202PubMedGoogle Scholar
  28. 28.
    Carswell EA, Old LJ, Kassel RL, Greens S, Fiore N, Williamson B (1975) An endotoxin-in- duced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666PubMedCrossRefGoogle Scholar
  29. 29.
    Herrmann F (1988) Tumornekrosefaktor. Molekularbiologische und biochemische Grundlagen, biologische Aktivität, klinische Anwendungsmöglichkeiten. MMW128: 630Google Scholar
  30. 30.
    Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, Waltersdorph AM (1986) Stimulation of neutrophils by tumor necrosis factor. J Immunol 136: 4220PubMedGoogle Scholar
  31. 31.
    Philip R, Epstein LM (1986) Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 323: 80CrossRefGoogle Scholar
  32. 32.
    Ortaldo JR, Ransom JR, Sayers TJ, Herbermann RB (1986) Analysis of cytostatic/cytotoxic lymphokines: relationship of natural killer cytotoxic factor to recombinant lymphotoxin, recombinant tumor necrosis factor, and leukoregulin. J Immunol 137: 2587Google Scholar
  33. 33.
    Scheurich P, Thoma B, Ücer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor ( TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138: 1786Google Scholar
  34. 34.
    Old LJ (1985) Tumor necrosis factor (TNF). Science 230: 630PubMedCrossRefGoogle Scholar
  35. 35.
    Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. Nature 316: 379Google Scholar
  36. 36.
    Kehl JH, Miller A, Bauci AS (1987) Effect of tumor necrosis factor alpha on mitogen-activated human B cells. J Exp Med 166: 786CrossRefGoogle Scholar
  37. 37.
    Blick M, Sherwin SA, Rosenblum M, Guttermann J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47: 2986PubMedGoogle Scholar
  38. 38.
    Mertelsmann R, Gamm H, Flener R, Herrmann F (1987) Recombinant human tumor necrosis factor alpha in advanced cancer. A phase I clinical trial. Proc Am Ass Cancer Res 28: 399 (abstract 1583)Google Scholar
  39. 39.
    Chapman PB, Lester TL, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5: 1942PubMedGoogle Scholar
  40. 40.
    Herrmann F (1988) Polypeptides controlling hemopoietic growth and function. Blut (to be published)Google Scholar
  41. 41.
    Donahue RE, Wang E A, Stone D, Kamen R, Wong GG, Seghai PK, Nathan DG, Clark SC (1986) Stimulation of hematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 321: 872PubMedCrossRefGoogle Scholar
  42. 42.
    Lindemann A, Oster W, Ziegler-Heitbrock HWL, Mertelsmann R, Herrmann F (1988) Granulocyte-macrophage colony-stimulating factor induces cytokines secretion by polymorphonu-clear neutrophils. J Clin Invest (to be published )Google Scholar
  43. 43.
    Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JU, Klebanoff SJ, Waltersdorph A, Wong G, Clark SC, Vadas MA (1986) Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 78: 1220PubMedCrossRefGoogle Scholar
  44. 44.
    Grabstein KH, Urdal DL, Tuschinski J, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Conoln PJ (1986) Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506PubMedCrossRefGoogle Scholar
  45. 45.
    Groopman JE, Mitsuyasu RT, DeLeo MJ, Oette DH, Golde DW (1987) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317: 593PubMedCrossRefGoogle Scholar
  46. 46.
    Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R (1988) Hematopoietic responses in patients with advanced malignancy treated with recombi-nant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol (to be published )Google Scholar
  47. 47.
    Arnaout MA, Wang E A, Clark SC, Sieff CA (1986) Human recombinant granulocyte-macro-phage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion promoting surface glycoproteins on mature granulocytes. J Clin Invest 78: 597PubMedCrossRefGoogle Scholar
  48. 48.
    Gabrilove J, Jacubowski A, Fain K, Scher H, Grous J, Sternberg C, Yogoda A, Clarkson B, Moore MAS, Bonilla MA, Oettgen HF, Alton K, Downing M, Welte K, Souza LM (1987) A phase I/II study of rhG-CSF in cancer patients at risk for chemotherapy-induced neuropenia. Blood [Suppl 1] 70: 135a (abstract 394)Google Scholar
  49. 49.
    Welte K, Platzer E, Lu L, Gabrilove J, Mertelsmann R, Moore MAS (1985) Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 82: 1526PubMedCrossRefGoogle Scholar
  50. 50.
    Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chenk K, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Welte K (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232: 261CrossRefGoogle Scholar
  51. 51.
    Cohen AM, Zsebo KM, Inoue H, Hines D, Boone TC, Chazin VR, Tsai L, Ritch T, Souza LM (1986) In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimualting factor. Proc Natl Acad Sci USA 84: 2484CrossRefGoogle Scholar
  52. 52.
    Welte K, Bonilla MA, Gillio AP, Potter GK, Boone TC, Potter GK, Gabrilove JC, Moore MAS, O’Reilly R, Souza LM (1987) Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 165: 941Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • A. Lindemann
    • 1
  • F. Herrmann
    • 1
  • H. Gamm
    • 1
  • W. Oster
    • 1
  • R. Mertelsmann
    • 1
  1. 1.Department of HematologyUniversity Clinic MainzMainzGermany

Personalised recommendations